gRNA Targeting Beta4GalNT2 for Xenotransplantation Graft Compatibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current xenotransplantation therapies face significant immune rejection issues due to the presence of genes encoding proteins that induce immune responses, necessitating effective gene knockout strategies to improve graft compatibility.
Innovation Solution
A gRNA specifically targeting the β4GalNT2 gene, combined with gRNAs targeting GGTA1 and CMAH genes, is used to achieve high and stable gene knockout efficiency, potentially reducing immune rejection by modifying the genetic makeup of xenotransplantation donors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If standard unmodified heterologous graft is used for xenotransplantation, then graft availability is improved, but immune rejection increases
Solution Approach 1:
The patent applies parameter changes by modifying the genetic composition of the graft through CRISPR/Cas9 gene editing. Specific genes (GGTA1, CMAH, β4GalNT2) are knocked out to alter the antigenic properties of the xenograft, changing the immunological parameters to reduce rejection while maintaining graft functionality.
Solution Approach 2:
The patent extracts and removes specific harmful genetic elements (GGTA1, CMAH, β4GalNT2 genes) that encode immunogenic proteins. By selectively eliminating these specific genes responsible for immune rejection, the graft becomes more compatible while retaining necessary functional genes.
2Object-affected harmful factors
If multiple genes are knocked out simultaneously to reduce immune rejection, then immune compatibility is improved, but gene editing complexity increases
Solution Approach 1:
The patent merges multiple gene knockout operations into a single integrated CRISPR/Cas9 editing process. Multiple guide RNAs targeting different genes (GGTA1, CMAH, β4GalNT2) are delivered simultaneously with Cas9, enabling concurrent editing of multiple genomic loci in one transformation event, thereby reducing overall process complexity.
Solution Approach 2:
The patent employs a universal CRISPR/Cas9 platform that can target multiple different genes through interchangeable guide RNAs. The same Cas9 protein and basic editing machinery serve multiple functions by directing different gRNAs to different genomic targets, simplifying the system compared to using separate editing tools for each gene.
3Ease of operation
If conventional gene knockout methods are used, then procedure simplicity is maintained, but knockout efficiency decreases
Solution Approach 1:
The patent replaces conventional mechanical/chemical gene disruption methods (such as random mutagenesis or targeted nucleases requiring separate cloning steps) with the CRISPR/Cas9 RNA-guided system. This substitution enables precise, efficient gene knockout through sequence-specific RNA-DNA pairing, dramatically improving knockout efficiency while maintaining procedural simplicity through standardized delivery methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The gRNA combination significantly enhances gene knockout efficiency, allowing for the simultaneous knockout of multiple genes, thereby improving the compatibility and reducing immune rejection in xenotransplantation, as demonstrated by increased knockout efficiencies up to 50% or more.
Implementation Method 1
the said gRNA specifically binds to a nucleotide sequence as set forth in any one of SEQ ID NOs. 1-2
Data Source
AI summary
Provided is gRNA specifically targeting β4GalNT2 gene. The gRNA specifically binds to the nucleotide sequence shown in any one of SEQ ID NOs. 1 and 2. Also provided are an animal model constructed using the gRNA, and an application thereof in the field of biomedicine.